355 related articles for article (PubMed ID: 7584112)
1. Inhibition of HIV-1 in CEM cells by a potent TAR decoy.
Lee SW; Gallardo HF; Gaspar O; Smith C; Gilboa E
Gene Ther; 1995 Aug; 2(6):377-84. PubMed ID: 7584112
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain.
Lee SW; Gallardo HF; Gilboa E; Smith C
J Virol; 1994 Dec; 68(12):8254-64. PubMed ID: 7966618
[TBL] [Abstract][Full Text] [Related]
3. High level inhibition of HIV replication with combination RNA decoys expressed from an HIV-Tat inducible vector.
Fraisier C; Irvine A; Wrighton C; Craig R; Dzierzak E
Gene Ther; 1998 Dec; 5(12):1665-76. PubMed ID: 10023446
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of RRE-derived sequences inhibits HIV-1 replication in CEM cells.
Lee TC; Sullenger BA; Gallardo HF; Ungers GE; Gilboa E
New Biol; 1992 Jan; 4(1):66-74. PubMed ID: 1536832
[TBL] [Abstract][Full Text] [Related]
5. SV40-derived vectors provide effective transgene expression and inhibition of HIV-1 using constitutive, conditional,and pol III promoters.
Jayan GC; Cordelier P; Patel C; BouHamdan M; Johnson RP; Lisziewicz J; Pomerantz RJ; Strayer DS
Gene Ther; 2001 Jul; 8(13):1033-42. PubMed ID: 11438838
[TBL] [Abstract][Full Text] [Related]
6. Retroviral vector with a CMV-IE/HIV-TAR hybrid LTR gives high basal expression levels and is up-regulated by HIV-1 Tat.
Robinson D; Elliott JF; Chang LJ
Gene Ther; 1995 Jun; 2(4):269-78. PubMed ID: 7552987
[TBL] [Abstract][Full Text] [Related]
7. Block of HIV-1 infection by a combination of antisense tat RNA and TAR decoys: a strategy for control of HIV-1.
Chang HK; Gendelman R; Lisziewicz J; Gallo RC; Ensoli B
Gene Ther; 1994 May; 1(3):208-16. PubMed ID: 7584083
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by HIV-1-based lentivirus vectors expressing transdominant Rev.
Mautino MR; Keiser N; Morgan RA
J Virol; 2001 Apr; 75(8):3590-9. PubMed ID: 11264348
[TBL] [Abstract][Full Text] [Related]
9. Infection and replication of Tat- human immunodeficiency viruses: genetic analyses of LTR and tat mutations in primary and long-term human lymphoid cells.
Chang LJ; Zhang C
Virology; 1995 Aug; 211(1):157-69. PubMed ID: 7645208
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of simian/human immunodeficiency virus replication in CD4+ T cells derived from lentiviral-transduced CD34+ hematopoietic cells.
Braun SE; Wong FE; Connole M; Qiu G; Lee L; Gillis J; Lu X; Humeau L; Slepushkin V; Binder GK; Dropulic B; Johnson RP
Mol Ther; 2005 Dec; 12(6):1157-67. PubMed ID: 16168713
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of HIV-1 replication in viral mutants with altered TAR RNA stem structures.
Rounseville MP; Lin HC; Agbottah E; Shukla RR; Rabson AB; Kumar A
Virology; 1996 Feb; 216(2):411-7. PubMed ID: 8607271
[TBL] [Abstract][Full Text] [Related]
12. Antitat gene therapy: a candidate for late-stage AIDS patients.
Lisziewicz J; Sun D; Lisziewicz A; Gallo RC
Gene Ther; 1995 May; 2(3):218-22. PubMed ID: 7614253
[TBL] [Abstract][Full Text] [Related]
13. Long-term protection against HIV-1 infection conferred by tat or rev antisense RNA was affected by the design of the retroviral vector.
Peng H; Callison D; Li P; Burrell C
Virology; 1996 Jun; 220(2):377-89. PubMed ID: 8661389
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of HIV-1 transcription and virus replication using soluble Tat peptide analogs.
Kashanchi F; Sadaie MR; Brady JN
Virology; 1997 Jan; 227(2):431-8. PubMed ID: 9018142
[TBL] [Abstract][Full Text] [Related]
15. Transient protection of human T-cells from human immunodeficiency virus type 1 infection by transduction with adeno-associated viral vectors which express RNA decoys.
Smith C; Lee SW; Wong E; Gallardo H; Page K; Gaspar O; Lebkowski J; Gilboa E
Antiviral Res; 1996 Oct; 32(2):99-115. PubMed ID: 8891169
[TBL] [Abstract][Full Text] [Related]
16. The TAR hairpin of human immunodeficiency virus type 1 can be deleted when not required for Tat-mediated activation of transcription.
Das AT; Harwig A; Vrolijk MM; Berkhout B
J Virol; 2007 Jul; 81(14):7742-8. PubMed ID: 17494072
[TBL] [Abstract][Full Text] [Related]
17. Tat is required for efficient HIV-1 reverse transcription.
Harrich D; Ulich C; García-Martínez LF; Gaynor RB
EMBO J; 1997 Mar; 16(6):1224-35. PubMed ID: 9135139
[TBL] [Abstract][Full Text] [Related]
18. Block of Tat-mediated transactivation of tumor necrosis factor beta gene expression by polymeric-TAR decoys.
Brother MB; Chang HK; Lisziewicz J; Su D; Murty LC; Ensoli B
Virology; 1996 Aug; 222(1):252-6. PubMed ID: 8806505
[TBL] [Abstract][Full Text] [Related]
19. Antisense RNA sequences targeting the 5' leader packaging signal region of human immunodeficiency virus type-1 inhibits viral replication at post-transcriptional stages of the life cycle.
Chadwick DR; Lever AM
Gene Ther; 2000 Aug; 7(16):1362-8. PubMed ID: 10981662
[TBL] [Abstract][Full Text] [Related]
20. Hydrogen-bonding contacts in the major groove are required for human immunodeficiency virus type-1 tat protein recognition of TAR RNA.
Hamy F; Asseline U; Grasby J; Iwai S; Pritchard C; Slim G; Butler PJ; Karn J; Gait MJ
J Mol Biol; 1993 Mar; 230(1):111-23. PubMed ID: 8450529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
